ICP-248 is under clinical development by InnoCare Pharma and currently in Phase I for B-Cell Non-Hodgkin Lymphoma. According to GlobalData, Phase I drugs for B-Cell Non-Hodgkin Lymphoma have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ICP-248’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ICP-248 overview
ICP-248 is under development for the treatment of relapsed and refractory hematological malignancies including mature B-cell malignancies including B-cell non-Hodgkin lymphoma (B-NHL), chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), marginal zone lymphoma (MZL), lymphoplasmacytic lymphoma (LPL), acute lymphocytic leukemia (ALL), acute myelocytic leukemia (AML) and relapsed and refractory acute myeloid leukemia. It is administered through oral route. The drug candidate acts by targeting apoptosis regulator BCL2.
InnoCare Pharma overview
InnoCare Pharma (InnoCare) is a biopharmaceutical company that discovers and develops novel treatments for cancer and autoimmune diseases. The company’s pipeline products include orelabrutinib and tafasitamab target autoimmune diseases and hemato-oncology indications; Gunagratinib (ICP-192) a novel compound that targets cholangiocarcinoma and urothelial cancer; ICP-033, ICP-189 and ICP-B05 for solid tumors; and Zurletrectinib (ICP-723) treat NTRK fusion-positive cancers. It operates in the US and China. InnoCare is headquartered in Changping, Beijing, China.
For a complete picture of ICP-248’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
